Antibodies
Assay Kits
Biology Cells
Clia Kits
Culture Cells
Devices
DNA Templates
Elisa Kits
enox2 antibody
Equipments
Exosomes
fgfr4 antibody
galt antibody
Gels
grk5 antibody
Isotypes
kisspeptin antibody
klhl22 antibody
Medium & Serums
NATtrol
neomarkers antibody
Panel
Particles
PCR
Pcr Kits
Peptides
Reagents
Recombinant Proteins
Ria Kits
Test Kits
usp28 antibody
Vector & Virus
Western Blot
DNA damage in lens epithelial cells exposed to occupationally-relevant X-ray doses and role in cataract formation
The present framework of radiological safety of occupational uncovered medical employees decreased the eye-lens equal dose restrict from 150 to 20 mSv per yr requiring an correct dosimetric analysis and a rise understanding of radiation induced results on Lens cells contemplating the standard situation of occupational uncovered medical operators. Certainly, it’s broadly accepted that genomic harm of Lens epithelial cells (LEC) is a key mechanism of cataractogenesis. Nevertheless, the connection between apoptosis and cataractogenesis continues to be controversial. On this research organic and bodily information are mixed to enhance the understanding of radiation induced results on LEC. To characterize the occupational publicity of medical employees throughout angiographic procedures an INNOVA 4100 (Basic Electrical Healthcare) gear was used (situation A).
Further experiments have been carried out utilizing a analysis tube (situation B). For each situations, the frequencies of binucleated cells, micronuclei, p21-positive cells have been assessed with totally different doses and dose charges. A Monte-Carlo research was carried out utilizing a mannequin for the photon technology with the X-ray tubes and with the Petri dishes contemplating the 2 totally different situations (A and B) to breed the experimental circumstances and validate the irradiation setups to the cells. The simulation outcomes have been tallied utilizing the Monte Carlo code MCNP6. The spectral traits of the totally different X-ray beams have been estimated.
All irradiated samples confirmed frequencies of micronuclei and p21-positive cells increased than the unirradiated controls. Variations in frequencies elevated with the delivered dose measured with Gafchromic movies XR-RV3. The spectrum incident on eye lens and Petri, as estimated with MCNP6, was in good settlement within the situation A (confirming the experimental setup), whereas the imply power spectrum was increased within the situation B. Nonetheless, the response of LEC appeared primarily associated to the measured absorbed dose. No results on viability have been detected. Our outcomes assist the speculation that apoptosis shouldn’t be answerable for cataract induced by low doses of X-ray (i.e. 25 mGy) whereas the induction of transient p21 might intervene with the disassembly of the nuclear envelop in differentiating LEC, resulting in cataract formation. Additional research are wanted to raised make clear the connection we recommended between DNA harm, transient p21 induction and the lack of LEC enucleation.
Specs of the ACMG/AMP variant interpretation pointers for germline TP53 variants
Germline pathogenic variants in TP53 are related to Li-Fraumeni syndrome (LFS), a most cancers predisposition dysfunction inherited in an autosomal dominant sample related to excessive threat of malignancy, together with early onset breast cancers, sarcomas, adrenocortical carcinomas, and mind tumors. Intense most cancers surveillance for people with TP53 germline pathogenic variants is related to decreased cancer-related mortality. Correct and constant classification of germline variants throughout scientific and analysis laboratories is vital to make sure acceptable most cancers surveillance suggestions. Right here, we describe the work carried out by the Scientific Genome Useful resource TP53 Variant Curation Knowledgeable Panel (ClinGen TP53 VCEP) targeted on specifying the American Faculty of Medical Genetics and Genomics and the Affiliation for Molecular Pathology (ACMG/AMP) pointers for germline variant classification to the TP53 gene.
Specs have been developed for twenty ACMG/AMP standards whereas 9 have been deemed not relevant. The unique power degree for ten standards was additionally adjusted as a result of present proof. Use of TP53-specific pointers and sharing of scientific information amongst specialists and scientific laboratories led to a lower in variants of unsure significance from 28% to 12% in contrast with the unique pointers. The ClinGen TP53 VCEP recommends the usage of these TP53-specific ACMG/AMP pointers as the usual technique for TP53 germline variant classification. This text is protected by copyright. All rights reserved.
Measurement of genetic illnesses as a reason for mortality in infants receiving complete genome sequencing
Understanding causes of toddler mortality shapes public well being coverage and prioritizes illnesses for investments in surveillance, intervention and medical analysis. Fast genomic sequencing has created a novel alternative to lower toddler mortality related to treatable genetic illnesses. Herein, we sought to measure the contribution of genetic illnesses to mortality amongst infants by secondary evaluation of infants enrolled in two scientific research and a scientific literature assessment.
Amongst 312 infants who had been admitted to an ICU at Rady Youngsters’s Hospital between November 2015 and September 2018 and obtained speedy genomic sequencing, 30 (10%) died in infancy. Ten (33%) of the infants who died have been identified with 11 genetic illnesses. The San Diego Examine of Outcomes in Moms and Infants platform recognized variations between in-hospital and out-of-hospital causes of toddler dying. Equally, in six printed research, 195 (21%) of 918 toddler deaths have been related to genetic illnesses by genomic sequencing. In 195 toddler deaths related to genetic illnesses, locus heterogeneity was 70%. Remedy pointers existed for 70% of the genetic illnesses identified, suggesting that speedy genomic sequencing has substantial potential to lower toddler mortality amongst infants in ICUs. Additional research are wanted in bigger, complete, unbiased affected person units to find out the generalizability of those findings.
 Trypsin, Recombinant, Proteomics grade |
|||
| P1228-5000 | Biovision | EUR 615 | |
 Antibody) CD8(C8/468 + C8/144B) Antibody |
|||
| BNUB0750-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Concentration: 0.2mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNUB0750-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Concentration: 0.2mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNUM0750-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), 1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC040750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC040750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC550750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC550750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC610750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC610750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC470750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC470750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC050750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC050750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC400750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF640R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC400750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF640R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC430750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF543 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC430750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF543 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC800750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF680 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC800750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF680 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCP0750-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), PerCP conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCR0750-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), RPE conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCA0750-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), APC conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCAP0750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCAP0750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCB0750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Biotin conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCB0750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Biotin conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCH0750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNCH0750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC940750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF594 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC940750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF594 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC680750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF568 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC680750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF568 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC700750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF770 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC700750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF770 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC880750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF488A conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC880750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF488A conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC810750-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF680R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468 + C8/144B) Antibody |
|||
| BNC810750-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468 + C8/144B), CF680R conjugate, Concentration: 0.1mg/mL |
|||
 C8 Ceramide |
|||
| 20-abx076676 | Abbexa |
|
|
|
|||
 Complement C8 antibody |
|||
| 20C-CR2038G | Fitzgerald | 1 ml | EUR 187 |
|
Description: Goat polyclonal Complement C8 antibody |
|||
|
Complement C8 antibody |
|||
| 20C-CR6024SP | Fitzgerald | 1 ml | EUR 295 |
|
Description: Sheep polyclonal Complement C8 antibody |
|||
 C8 ? Polyclonal Antibody |
|||
| ES8518-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against C8 ? from Human/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
|
C8 ? Polyclonal Antibody |
|||
| ES8518-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against C8 ? from Human/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
|
C8 ? Polyclonal Antibody |
|||
| ES8864-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against C8 ? from Human. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
|
C8 ? Polyclonal Antibody |
|||
| ES8864-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against C8 ? from Human. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
 AlbuVoid™ LC-MS On-Bead For Serum Proteomics |
|||
| AVB-MS05 | Biotech Support Group | 5 preps | EUR 379 |
|
Description: Albumin Removal Kit |
|||
|
AlbuVoid™ LC-MS On-Bead For Serum Proteomics |
|||
| AVB-MS10 | Biotech Support Group | 10 preps | EUR 521 |
|
Description: Albumin Removal Kit |
|||
 HemoVoid™ LC-MS On-Bead For Erythrocytes Proteomics |
|||
| HVB-MS05 | Biotech Support Group | 5 preps | EUR 379 |
|
Description: Hemoglobin Removal Kit |
|||
|
HemoVoid™ LC-MS On-Bead For Erythrocytes Proteomics |
|||
| HVB-MS10 | Biotech Support Group | 10 preps | EUR 521 |
|
Description: Hemoglobin Removal Kit |
|||
 Anti-CD8A Antibody Clone C8/468 + C8/144B, Unconjugated-100ug |
|||
| 925-MSM3-P1 | EnQuireBio | 100ug | EUR 428 |
 C8 α Polyclonal Antibody |
|||
| 46913-100ul | SAB | 100ul | EUR 252 |
|
C8 α Polyclonal Antibody |
|||
| 46913-50ul | SAB | 50ul | EUR 187 |
 Anti-C8 beta Antibody |
|||
| A07152 | BosterBio | 100ul | EUR 397 |
|
Description: Rabbit Polyclonal Antibody for C8 beta Antibody (C8B) detection. Tested with WB in Human, Rat. |
|||
 Human Complement C8 Antibody |
|||
| 15351-05011 | AssayPro | 150 ug | EUR 217 |
|
Human Complement C8 Antibody |
|||
| 45351-05011 | AssayPro | 150 ug | EUR 217 |
 Antibody) CD8(C8/1035) Antibody |
|||
| BNUM1035-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against CD8(C8/1035), 1mg/mL |
|||
 Antibody) CD8(C8/468) Antibody |
|||
| BNUB0468-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against CD8(C8/468), Concentration: 0.2mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNUB0468-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against CD8(C8/468), Concentration: 0.2mg/mL |
|||
 Antibody) CD8(C8/144B) Antibody |
|||
| BNUB0749-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against CD8(C8/144B), Concentration: 0.2mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNUB0749-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against CD8(C8/144B), Concentration: 0.2mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNUB1035-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against CD8(C8/1035), Concentration: 0.2mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNUB1035-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against CD8(C8/1035), Concentration: 0.2mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNUM0468-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against CD8(C8/468), 1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNUM0749-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against CD8(C8/144B), 1mg/mL |
|||
-CP 47,497-C8-homolog) (±)-CP 47,497-C8-homolog |
|||
| B7940-10 | ApexBio | 10 mg | EUR 206 |
|
(±)-CP 47,497-C8-homolog |
|||
| B7940-25 | ApexBio | 25 mg | EUR 419 |
|
(±)-CP 47,497-C8-homolog |
|||
| B7940-5 | ApexBio | 5 mg | EUR 132 |
|
CD8(C8/468) Antibody |
|||
| BNC040468-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC040468-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC040749-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/144B), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC040749-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/144B), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC550749-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/144B), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC550749-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/144B), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC551035-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/1035), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC551035-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/1035), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC610468-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC610468-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC610749-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/144B), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC610749-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/144B), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC611035-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/1035), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC611035-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/1035), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC470468-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC470468-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC470749-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/144B), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC470749-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/144B), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC471035-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/1035), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC471035-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/1035), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC550468-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC550468-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC050468-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC050468-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC050749-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/144B), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/144B) Antibody |
|||
| BNC050749-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/144B), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC051035-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/1035), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/1035) Antibody |
|||
| BNC051035-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/1035), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC400468-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against CD8(C8/468), CF640R conjugate, Concentration: 0.1mg/mL |
|||
|
CD8(C8/468) Antibody |
|||
| BNC400468-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against CD8(C8/468), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Widespread information fashions (CDMs) assist standardize digital well being document information and facilitate end result evaluation for observational and longitudinal analysis. An evaluation of pathology experiences is required to determine basic info infrastructure for data-driven colon most cancers analysis. The Observational Medical Outcomes Partnership (OMOP) CDM is utilized in distributed analysis networks for scientific information; nonetheless, it requires conversion of free text-based pathology experiences into the CDM’s format. There are few use instances of representing most cancers information in CDM.